Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia (April 2022)

Friday, June 3, 2022

From January to April 2022, Russian manufacturers produced 258.8 billion rubles’ worth of pharmaceutical drugs (manufacturer’s prices, VAT included), up 29.3% from the same period in 2021. In physical terms, the production volume was 1.47 billion packages, up 3.5% from the year before. However, if calculated in minimum dosage units (MDU), the production volume was 26.9 billion, up only 1.3%.

The rush demand and the sharp increase in production in March were naturally followed by a recession in April. The growth rate in April against March was –4.5% in rubles and –14.7% in packages, which is actually a standard spring trend. The growth rate against April 2021 was as high as 35.9% in rubles and 9.5% in packages, though. In MDUs, however, it was –1.8%, but that is completely normal. Despite the issues with the supply of raw materials and components, the Russian pharmaceutical industry has so far been able to avoid any major difficulties since the start of the crisis. There have not been any obvious anti-crisis strategies yet; the manufacturers have not increased the number of single doses in a package in order to save packaging materials, etc. Besides, compared to 2021, the manufacturers seem to be doing quite the opposite—decreasing the number of doses in packages, especially in OTC categories.

These change led to noticeable differences in the growth rates by product groups. In January–April 2022, the production of OTC drug went up by 11.6% in packages from the same period in 2021. As for the Rx category, the growth rate was negative, –5%. However, if calculated in MDUs, the situation is reversed: –2% for OTC and +4.3% for prescription drugs.

Usolpharm had an all-time high growth rate in January-April 2022 among the top 20 manufacturers of OTC drugs. The company’s manufacture increased 23.2 times from January-April 2021, with Corvalol, Salicylic Ointment, and Balsamic Liniment Wishnevsky contributing to the growth rates the most. Usolpharm is followed by Vifiteh (manufacture grew 6.6 times); its Mucaltin helped contribute to the growth rates, accounting for around 38% of the total production volume. Uralbiofarm rounds up the top three, having increasing its manufacture 2.9 times from 2021. Citramon and Acetylsalicylic Acid contributed to the company’s growth rates the most.

As for the manufacturers of prescription drugs, ProMed (+64%), Pharmstandard (+33%), Severnaya Zvezda (+32%) had the best growth rates in January–April 2022. Omeprazole contributed to the growth rates of ProMed (manufacture doubled). Pharmstandard’s Taufon (production grew 2.9 times in physical terms) and Combilipen (2.5 times) helped increase the company’s growth rates. In the case of Severnaya Zvezda, Moxinidine, Torasemide, and Sildenafil contributed to the growth rates the most.

Production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (packages) and monetary terms (RUB, VAT included) (January 2021–April 2022)